225 related articles for article (PubMed ID: 15655130)
1. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study.
Sola S; Mir MQ; Cheema FA; Khan-Merchant N; Menon RG; Parthasarathy S; Khan BV
Circulation; 2005 Jan; 111(3):343-8. PubMed ID: 15655130
[TBL] [Abstract][Full Text] [Related]
2. AT1-receptor blockade with irbesartan improves peripheral but not coronary endothelial dysfunction in patients with stable coronary artery disease.
Warnholtz A; Ostad MA; Heitzer T; Thuneke F; Fröhlich M; Tschentscher P; Schwedhelm E; Böger R; Meinertz T; Munzel T
Atherosclerosis; 2007 Oct; 194(2):439-45. PubMed ID: 16970950
[TBL] [Abstract][Full Text] [Related]
3. [Effects of angiotensin receptor blocker and angiotensin-coverting enzyme inhibitor on vascular endothelial function in type 2 diabetic patients with atherosclerosis: a comparative study].
Wang L; Huang XS; Zhou YL; Chen JY; Lin SG
Di Yi Jun Yi Da Xue Xue Bao; 2005 Aug; 25(8):967-71. PubMed ID: 16109551
[TBL] [Abstract][Full Text] [Related]
4. Effect of long-term irbesartan treatment on endothelium-dependent vasodilation in essential hypertensive patients.
Bragulat E; Larrousse M; Coca A; de la Sierra A
Br J Biomed Sci; 2003; 60(4):191-6. PubMed ID: 14725334
[TBL] [Abstract][Full Text] [Related]
5. Treatment with irbesartan or atenolol improves endothelial function in essential hypertension.
von zur Mühlen B; Kahan T; Hägg A; Millgård J; Lind L
J Hypertens; 2001 Oct; 19(10):1813-8. PubMed ID: 11593101
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin II receptor blockers improve endothelial dysfunction associated with sympathetic hyperactivity in metabolic syndrome.
Kishi T; Hirooka Y; Konno S; Sunagawa K
J Hypertens; 2012 Aug; 30(8):1646-55. PubMed ID: 22728908
[TBL] [Abstract][Full Text] [Related]
7. Alpha-lipoic acid improves endothelial dysfunction in patients with subclinical hypothyroidism.
G D X; J H P; H L S; L S Z
Exp Clin Endocrinol Diabetes; 2010 Oct; 118(9):625-9. PubMed ID: 20162509
[TBL] [Abstract][Full Text] [Related]
8. Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension.
Koh KK; Han SH; Chung WJ; Ahn JY; Jin DK; Kim HS; Park GS; Kang WC; Ahn TH; Shin EK
Am J Cardiol; 2004 Jun; 93(11):1432-5, A10. PubMed ID: 15165934
[TBL] [Abstract][Full Text] [Related]
9. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha.
Derosa G; Cicero AF; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Ferrari I; Gravina A; Fogari R
Hypertens Res; 2006 Nov; 29(11):849-56. PubMed ID: 17345784
[TBL] [Abstract][Full Text] [Related]
10. α-lipoic acid can improve endothelial dysfunction in subjects with impaired fasting glucose.
Xiang G; Pu J; Yue L; Hou J; Sun H
Metabolism; 2011 Apr; 60(4):480-5. PubMed ID: 21255807
[TBL] [Abstract][Full Text] [Related]
11. Montelukast and irbesartan ameliorate metabolic and hepatic disorders in fructose-induced metabolic syndrome in rats.
Ibrahim MA; Amin EF; Ibrahim SA; Abdelzaher WY; Abdelrahman AM
Eur J Pharmacol; 2014 Feb; 724():204-10. PubMed ID: 24370493
[TBL] [Abstract][Full Text] [Related]
12. Combined treatment of irbesartan and diltiazem ameliorates endothelium dependent vasodilatation in hypertensives.
Zhou T; Huang X; Cai X; Xie L
Clin Exp Hypertens; 2017; 39(7):612-618. PubMed ID: 28613098
[TBL] [Abstract][Full Text] [Related]
13. Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study.
Mörtsell D; Malmqvist K; Held C; Kahan T
J Intern Med; 2007 May; 261(5):472-9. PubMed ID: 17444886
[TBL] [Abstract][Full Text] [Related]
14. Effects of AT1 receptor antagonism with candesartan on endothelial function in patients with hypertension and coronary artery disease.
Perrone-Filardi P; Corrado L; Brevetti G; Silvestro A; Dellegrottaglie S; Cafiero M; Caiazzo G; Petretta A; Maglione A; Monda C; Guerra G; Marzano A; Cesarano P; Gargiulo P; Chiariello M
J Clin Hypertens (Greenwich); 2009 May; 11(5):260-5. PubMed ID: 19534023
[TBL] [Abstract][Full Text] [Related]
15. Coenzyme Q(10) improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus.
Watts GF; Playford DA; Croft KD; Ward NC; Mori TA; Burke V
Diabetologia; 2002 Mar; 45(3):420-6. PubMed ID: 11914748
[TBL] [Abstract][Full Text] [Related]
16. Irbesartan, an angiotensin receptor blocker, exhibits metabolic, anti-inflammatory and antioxidative effects in patients with high-risk hypertension.
Taguchi I; Toyoda S; Takano K; Arikawa T; Kikuchi M; Ogawa M; Abe S; Node K; Inoue T
Hypertens Res; 2013 Jul; 36(7):608-13. PubMed ID: 23425956
[TBL] [Abstract][Full Text] [Related]
17. Effect of combined treatment with alpha-Lipoic acid and acetyl-L-carnitine on vascular function and blood pressure in patients with coronary artery disease.
McMackin CJ; Widlansky ME; Hamburg NM; Huang AL; Weller S; Holbrook M; Gokce N; Hagen TM; Keaney JF; Vita JA
J Clin Hypertens (Greenwich); 2007 Apr; 9(4):249-55. PubMed ID: 17396066
[TBL] [Abstract][Full Text] [Related]
18. Effects of estradiol and the angiotensin II receptor blocker irbesartan on vascular function in postmenopausal women.
Mirza FS; Ong P; Collins P; Okamura K; Gerhard-Herman M; Williams GH; Seely EW
Menopause; 2008; 15(1):44-50. PubMed ID: 18182939
[TBL] [Abstract][Full Text] [Related]
19. Mesoglycan improves vascular reactivity and insulin sensitivity in patients with metabolic syndrome.
Valvano A; Bosso G; Apuzzi V; Riccone F; Saccà L; Oliviero U
Atherosclerosis; 2015 Dec; 243(2):407-13. PubMed ID: 26520894
[TBL] [Abstract][Full Text] [Related]
20. The antioxidant alpha-lipoic acid improves endothelial dysfunction induced by acute hyperglycaemia during OGTT in impaired glucose tolerance.
Xiang GD; Sun HL; Zhao LS; Hou J; Yue L; Xu L
Clin Endocrinol (Oxf); 2008 May; 68(5):716-23. PubMed ID: 18070144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
